chartexchange

The Precision Peptide Company's Needle-Free First Strategy Already in Place as HHS Draft Policy Recognizes Non-Injectable Routes for Leading Peptides

Newsfile | Nov 3, 2026 7:00 AM EST

HighlightsFederal path for BPC-157: HHS has published a draft Enforcement Discretion Policy concerning a potential interim 503A compounding path for six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500Needle-free routes recognized: oral and topical forms for BPC-157 and KPV, and intranasal use for Semax, now sit alongside injection in federal policyBuilt for the Company's model: the Policy runs through 503A compounding, a similar U.S. pathway behind the Company's 16-therapy...

Read original article